Autologous Transplantation Of Hematopoietic Progenitors In Patients With Multiple Myeloma: Analysis Of Prognostic Factors And Survival. Experience Of The British Hospital

Introduction: autologic transplant of hematopoietic progenitors is regarded as the standard in the first line treatment of patients with multiple myeloma (MM) younger than 65 years old.Objective: to analyse global survival and incident free survival in patients with multiple myeloma transplanted at the British Hospital.Method: we conducted a retrospective study of patients who received the first autologic transplant of hematopoietic progenitors.Results: 56 autologic transplants of hematopoietic progenitors were performed from July 1, 1999 through June 30, 2010 in 48 patients with MM. Upon analysis of patients after the first transplant, 46% were women and 54% were men. Median age was 54 years old (32-65 years old). 73% were IgG, 17% were IgA and 10% were light chains. 60.4% achieved CR/nCR (CR), non-confirmed CR and VGPR) after transplant. With an average follow-up of 58.6 months (5.84-186.56), the median global survival was 121.8 months (IC 95%: 70.1-173.54 months). No significant differences were found in the global survival in patients who achieved CR/nCR after autologic transplant of hematopoietic progenitors and those who failed to achieve it (log Rank p=0.162. The median incident-free survival was 56 months (IC 95%: 42.2-70.4 months).Conclusions: autologic transplant of hematopoietic progenitors is an essential tool to treat patients with MM and it is a safe procedure at the Hematology Unit of the British Hospital.